Every material Form 8-K Boundless Bio, Inc. has filed with the SEC since May 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Boundless Bio signed Amendment No. 1 to its merger agreement with Serapha Bio on August 28, 2026, changing how Serapha equity awards, certain merger consideration and a share authorization vote are handled. The filing does not state a deal value, and the amendment otherwise leaves the original June 22, 2026 terms unchanged, so shareholders should watch the Form S-4 and proxy statement for the full effect.
Amendment No. 1 dated August 28, 2026; original Merger Agreement signed June 22, 2026 with Serapha Bio, Inc.
Serapha restricted stock units, vested or unvested, convert into Boundless Bio restricted stock units adjusted by the Exchange Ratio
Pre-funded warrants with a $0.00001 exercise price can be issued as merger consideration where share ownership limits would be exceeded
Authorized share increase now requires a majority of shares properly cast, rather than a majority of shares outstanding
Boundless Bio agreed on June 22, 2026 to an all-stock merger with privately held Serapha Bio, a clinical-stage company developing an in vivo base editing therapy for Alpha-1 Antitrypsin Deficiency. Boundless stockholders are expected to own about 3.69% of the combined company, and the company's CEO, Zachary Hornby, steps down effective July 1, 2026, which affects shareholders' stake and the company's management.
Merger agreement dated June 22, 2026; the combined company is expected to operate as Serapha Bio and trade as AATD, subject to Nasdaq approval
Pre-merger Boundless holders expected to own about 3.69% and Serapha holders about 96.31% of the combined company, fully diluted
Boundless may pay a pre-closing cash dividend; the press release says about $44 to $48 million, and the press release states the BBI-940 program will not be advanced
CEO Zachary Hornby steps down July 1, 2026; Chief Legal Officer Jessica Oien to serve as principal executive officer; closing expected in Q4 2026
Boundless Bio reported first-quarter 2026 results with a net loss of $13.6 million, down from $15.8 million a year earlier, as research and development and general and administrative expenses both fell. The company reported no revenue in the filing, and cash, cash equivalents and short-term investments declined to $92.8 million from $107.6 million at December 31, 2025, which it says will fund operations into the second half of 2028.
Net loss was $13.6 million for Q1 2026 versus $15.8 million for Q1 2025; net loss per share was $0.60 versus $0.71.
R&D expenses were $9.7 million versus $12.1 million a year earlier; G&A expenses were $4.7 million versus $5.2 million.
Cash and short-term investments were $92.8 million at March 31, 2026, down from $107.6 million at December 31, 2025.
The company expects cash to fund operations into the second half of 2028, with initial KOMODO-1 clinical proof-of-concept data expected within that runway.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Boundless Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →